Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C32H44O7 |
Molecular Weight | 540.6876 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 9 / 9 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CC(C)C(=O)OCC(=O)[C@@]12O[C@@H](O[C@@H]1C[C@H]3[C@@H]4CCC5=CC(=O)C=C[C@]5(C)[C@H]4[C@@H](O)C[C@]23C)C6CCCCC6
InChI
InChIKey=LUKZNWIVRBCLON-GXOBDPJESA-N
InChI=1S/C32H44O7/c1-18(2)28(36)37-17-25(35)32-26(38-29(39-32)19-8-6-5-7-9-19)15-23-22-11-10-20-14-21(33)12-13-30(20,3)27(22)24(34)16-31(23,32)4/h12-14,18-19,22-24,26-27,29,34H,5-11,15-17H2,1-4H3/t22-,23-,24-,26+,27+,29+,30-,31-,32+/m0/s1
Molecular Formula | C32H44O7 |
Molecular Weight | 540.6876 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 9 / 9 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
DescriptionCurator's Comment: description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/12054077
Curator's Comment: description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/12054077
Ciclesonide is a glucocorticoid receptor agonist indicated for the treatment of allergic rhinitis (Omnaris nasal spray) and asthma (Alvesco). It was also developed by Byk Gulden for chronic obstructive pulmonary disease (COPD), but no development had been reported for this indication since 1999. Ciclesonide is a pro-drug and rapidly metabolized to C21-desisobutyryl-ciclesonide which is more potent toward GR receptor than the parent drug.
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL2034 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Palliative | OMNARIS Approved UseOMNARIS Nasal Spray is indicated for the treatment of nasal symptoms associated with seasonal allergic rhinitis in adults and children 6 years of age and older and for the treatment of nasal symptoms associated with perennial allergic rhinitis in adults and adolescents 12 years of age and older. Launch Date2006 |
|||
Palliative | OMNARIS Approved UseOMNARIS Nasal Spray is indicated for the treatment of nasal symptoms associated with seasonal allergic rhinitis in adults and children 6 years of age and older and for the treatment of nasal symptoms associated with perennial allergic rhinitis in adults and adolescents 12 years of age and older. Launch Date2006 |
|||
Preventing | ALVESCO Approved UseAlvesco is an inhaled corticosteroid indicated for: Maintenance treatment of asthma as prophylactic therapy in adult and adolescent patients 12 years of age and older Launch Date2008 |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
59.2 nM EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/15139796 |
0.64 mg single, intravenous dose: 0.64 mg route of administration: Intravenous experiment type: SINGLE co-administered: |
CICLESONIDE serum | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
4 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/21296519/ |
400 μg single, respiratory dose: 400 μg route of administration: Respiratory experiment type: SINGLE co-administered: |
CICLESONIDE plasma | Homo sapiens population: HEALTHY age: UNKNOWN sex: FEMALE / MALE food status: UNKNOWN |
|
4.3 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/21296519/ |
400 μg 1 times / day multiple, respiratory dose: 400 μg route of administration: Respiratory experiment type: MULTIPLE co-administered: |
CICLESONIDE plasma | Homo sapiens population: HEALTHY age: UNKNOWN sex: FEMALE / MALE food status: UNKNOWN |
|
15.2 ng/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/20110036/ |
300 μg single, nasal dose: 300 μg route of administration: Nasal experiment type: SINGLE co-administered: |
DES-CICLESONIDE serum | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
59.1 ng/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/20110036/ |
300 μg single, nasal dose: 300 μg route of administration: Nasal experiment type: SINGLE co-administered: |
DES-CICLESONIDE serum | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
586.2 ng/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/20110036/ |
320 μg single, respiratory dose: 320 μg route of administration: Respiratory experiment type: SINGLE co-administered: |
DES-CICLESONIDE serum | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
35.3 ng/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/21501692/ |
282 μg single, nasal dose: 282 μg route of administration: Nasal experiment type: SINGLE co-administered: |
DES-CICLESONIDE serum | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
35.84 ng/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/21501692/ |
282 μg 1 times / day multiple, nasal dose: 282 μg route of administration: Nasal experiment type: MULTIPLE co-administered: |
DES-CICLESONIDE serum | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
0.31 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/21296519/ |
400 μg single, respiratory dose: 400 μg route of administration: Respiratory experiment type: SINGLE co-administered: |
DES-CICLESONIDE plasma | Homo sapiens population: HEALTHY age: UNKNOWN sex: FEMALE / MALE food status: UNKNOWN |
|
0.41 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/21296519/ |
400 μg 1 times / day multiple, respiratory dose: 400 μg route of administration: Respiratory experiment type: MULTIPLE co-administered: |
DES-CICLESONIDE plasma | Homo sapiens population: HEALTHY age: UNKNOWN sex: FEMALE / MALE food status: UNKNOWN |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
51 ng × min/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/21296519/ |
400 μg single, respiratory dose: 400 μg route of administration: Respiratory experiment type: SINGLE co-administered: |
CICLESONIDE plasma | Homo sapiens population: HEALTHY age: UNKNOWN sex: FEMALE / MALE food status: UNKNOWN |
|
62.3 ng × min/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/21296519/ |
400 μg 1 times / day multiple, respiratory dose: 400 μg route of administration: Respiratory experiment type: MULTIPLE co-administered: |
CICLESONIDE plasma | Homo sapiens population: HEALTHY age: UNKNOWN sex: FEMALE / MALE food status: UNKNOWN |
|
397.5 ng × h/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/20110036/ |
300 μg single, nasal dose: 300 μg route of administration: Nasal experiment type: SINGLE co-administered: |
DES-CICLESONIDE serum | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
2685 ng × h/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/20110036/ |
320 μg single, respiratory dose: 320 μg route of administration: Respiratory experiment type: SINGLE co-administered: |
DES-CICLESONIDE serum | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
260 ng × h/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/21501692/ |
282 μg single, nasal dose: 282 μg route of administration: Nasal experiment type: SINGLE co-administered: |
DES-CICLESONIDE serum | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
337.8 ng × h/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/21501692/ |
282 μg 1 times / day multiple, nasal dose: 282 μg route of administration: Nasal experiment type: MULTIPLE co-administered: |
DES-CICLESONIDE serum | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
65.4 ng × min/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/21296519/ |
400 μg single, respiratory dose: 400 μg route of administration: Respiratory experiment type: SINGLE co-administered: |
DES-CICLESONIDE plasma | Homo sapiens population: HEALTHY age: UNKNOWN sex: FEMALE / MALE food status: UNKNOWN |
|
81.4 ng × min/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/21296519/ |
400 μg 1 times / day multiple, respiratory dose: 400 μg route of administration: Respiratory experiment type: MULTIPLE co-administered: |
DES-CICLESONIDE plasma | Homo sapiens population: HEALTHY age: UNKNOWN sex: FEMALE / MALE food status: UNKNOWN |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
0.38 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/15139796 |
0.64 mg single, intravenous dose: 0.64 mg route of administration: Intravenous experiment type: SINGLE co-administered: |
CICLESONIDE serum | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
15 min EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/21296519/ |
400 μg single, respiratory dose: 400 μg route of administration: Respiratory experiment type: SINGLE co-administered: |
CICLESONIDE plasma | Homo sapiens population: HEALTHY age: UNKNOWN sex: FEMALE / MALE food status: UNKNOWN |
|
13 min EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/21296519/ |
400 μg 1 times / day multiple, respiratory dose: 400 μg route of administration: Respiratory experiment type: MULTIPLE co-administered: |
CICLESONIDE plasma | Homo sapiens population: HEALTHY age: UNKNOWN sex: FEMALE / MALE food status: UNKNOWN |
|
3.46 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/21501692/ |
282 μg single, nasal dose: 282 μg route of administration: Nasal experiment type: SINGLE co-administered: |
DES-CICLESONIDE serum | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
4.84 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/21501692/ |
282 μg 1 times / day multiple, nasal dose: 282 μg route of administration: Nasal experiment type: MULTIPLE co-administered: |
DES-CICLESONIDE serum | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
156 min EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/21296519/ |
400 μg single, respiratory dose: 400 μg route of administration: Respiratory experiment type: SINGLE co-administered: |
DES-CICLESONIDE plasma | Homo sapiens population: HEALTHY age: UNKNOWN sex: FEMALE / MALE food status: UNKNOWN |
|
224 min EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/21296519/ |
400 μg 1 times / day multiple, respiratory dose: 400 μg route of administration: Respiratory experiment type: MULTIPLE co-administered: |
DES-CICLESONIDE plasma | Homo sapiens population: HEALTHY age: UNKNOWN sex: FEMALE / MALE food status: UNKNOWN |
Funbound
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
1% |
800 μg single, intravenous dose: 800 μg route of administration: Intravenous experiment type: SINGLE co-administered: |
CICLESONIDE plasma | Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN |
Doses
Dose | Population | Adverse events |
---|---|---|
0.64 mg single, intravenous Dose: 0.64 mg Route: intravenous Route: single Dose: 0.64 mg Sources: |
healthy, 27.3 years (range: 19-40 years) Health Status: healthy Age Group: 27.3 years (range: 19-40 years) Sex: M Sources: |
|
6.9 mg single, oral |
healthy, 27.3 years (range: 19-40 years) Health Status: healthy Age Group: 27.3 years (range: 19-40 years) Sex: M Sources: |
|
640 ug 2 times / day multiple, respiratory Highest studied dose Dose: 640 ug, 2 times / day Route: respiratory Route: multiple Dose: 640 ug, 2 times / day Sources: |
unhealthy, 48.3 years (range: 17-70 years) Health Status: unhealthy Age Group: 48.3 years (range: 17-70 years) Sex: M+F Sources: |
|
10 mg single, oral Highest studied dose Dose: 10 mg Route: oral Route: single Dose: 10 mg Sources: |
healthy, adult Health Status: healthy Age Group: adult Sources: |
|
282 ug 1 times / day multiple, intranasal Highest studied dose Dose: 282 ug, 1 times / day Route: intranasal Route: multiple Dose: 282 ug, 1 times / day Sources: |
unhealthy, adult Health Status: unhealthy Age Group: adult Sources: |
Disc. AE: Burning sensation... AEs leading to discontinuation/dose reduction: Burning sensation (severe, 1 patient) Sources: |
2880 ug single, respiratory Highest studied dose Dose: 2880 ug Route: respiratory Route: single Dose: 2880 ug Sources: |
healthy, adult Health Status: healthy Age Group: adult Sources: |
|
100 ug 1 times / day steady, respiratory Dose: 100 ug, 1 times / day Route: respiratory Route: steady Dose: 100 ug, 1 times / day Sources: |
unhealthy, children |
Other AEs: Lobar pneumonia, Asthma... Other AEs: Lobar pneumonia (serious, 1 patient) Sources: Asthma (serious, 1 patient) Pyrexia (below serious, 6 patients) Ear infection (below serious, 5 patients) Pharyngitis (below serious, 5 patients) Rhinitis (below serious, 4 patients) Upper respiratory tract infection (below serious, 18 patients) Cough (below serious, 6 patients) Allergic rhinitis (below serious, 7 patients) |
200 ug 1 times / day steady, respiratory Dose: 200 ug, 1 times / day Route: respiratory Route: steady Dose: 200 ug, 1 times / day Sources: |
unhealthy, children |
Other AEs: Laryngitis, Epistaxis... Other AEs: Laryngitis (serious, 1 patient) Sources: Epistaxis (serious, 1 patient) Myringoplasty (serious, 1 patient) Ear infection (below serious, 3 patients) Influenza (below serious, 6 patients) Lower respiratory tract infection (below serious, 4 patients) Upper respiratory tract infection (below serious, 19 patients) Cough (below serious, 4 patients) |
200 ug 1 times / day steady, respiratory Dose: 200 ug, 1 times / day Route: respiratory Route: steady Dose: 200 ug, 1 times / day Sources: |
unhealthy |
Other AEs: Cough, Asthenia... Other AEs: Cough (below serious, 2 patients) Sources: Asthenia (below serious, 1 patient) Chest pain (below serious, 1 patient) Decreased activity (below serious, 1 patient) |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Burning sensation | severe, 1 patient Disc. AE |
282 ug 1 times / day multiple, intranasal Highest studied dose Dose: 282 ug, 1 times / day Route: intranasal Route: multiple Dose: 282 ug, 1 times / day Sources: |
unhealthy, adult Health Status: unhealthy Age Group: adult Sources: |
Upper respiratory tract infection | below serious, 18 patients | 100 ug 1 times / day steady, respiratory Dose: 100 ug, 1 times / day Route: respiratory Route: steady Dose: 100 ug, 1 times / day Sources: |
unhealthy, children |
Rhinitis | below serious, 4 patients | 100 ug 1 times / day steady, respiratory Dose: 100 ug, 1 times / day Route: respiratory Route: steady Dose: 100 ug, 1 times / day Sources: |
unhealthy, children |
Ear infection | below serious, 5 patients | 100 ug 1 times / day steady, respiratory Dose: 100 ug, 1 times / day Route: respiratory Route: steady Dose: 100 ug, 1 times / day Sources: |
unhealthy, children |
Pharyngitis | below serious, 5 patients | 100 ug 1 times / day steady, respiratory Dose: 100 ug, 1 times / day Route: respiratory Route: steady Dose: 100 ug, 1 times / day Sources: |
unhealthy, children |
Cough | below serious, 6 patients | 100 ug 1 times / day steady, respiratory Dose: 100 ug, 1 times / day Route: respiratory Route: steady Dose: 100 ug, 1 times / day Sources: |
unhealthy, children |
Pyrexia | below serious, 6 patients | 100 ug 1 times / day steady, respiratory Dose: 100 ug, 1 times / day Route: respiratory Route: steady Dose: 100 ug, 1 times / day Sources: |
unhealthy, children |
Allergic rhinitis | below serious, 7 patients | 100 ug 1 times / day steady, respiratory Dose: 100 ug, 1 times / day Route: respiratory Route: steady Dose: 100 ug, 1 times / day Sources: |
unhealthy, children |
Asthma | serious, 1 patient | 100 ug 1 times / day steady, respiratory Dose: 100 ug, 1 times / day Route: respiratory Route: steady Dose: 100 ug, 1 times / day Sources: |
unhealthy, children |
Lobar pneumonia | serious, 1 patient | 100 ug 1 times / day steady, respiratory Dose: 100 ug, 1 times / day Route: respiratory Route: steady Dose: 100 ug, 1 times / day Sources: |
unhealthy, children |
Upper respiratory tract infection | below serious, 19 patients | 200 ug 1 times / day steady, respiratory Dose: 200 ug, 1 times / day Route: respiratory Route: steady Dose: 200 ug, 1 times / day Sources: |
unhealthy, children |
Ear infection | below serious, 3 patients | 200 ug 1 times / day steady, respiratory Dose: 200 ug, 1 times / day Route: respiratory Route: steady Dose: 200 ug, 1 times / day Sources: |
unhealthy, children |
Cough | below serious, 4 patients | 200 ug 1 times / day steady, respiratory Dose: 200 ug, 1 times / day Route: respiratory Route: steady Dose: 200 ug, 1 times / day Sources: |
unhealthy, children |
Lower respiratory tract infection | below serious, 4 patients | 200 ug 1 times / day steady, respiratory Dose: 200 ug, 1 times / day Route: respiratory Route: steady Dose: 200 ug, 1 times / day Sources: |
unhealthy, children |
Influenza | below serious, 6 patients | 200 ug 1 times / day steady, respiratory Dose: 200 ug, 1 times / day Route: respiratory Route: steady Dose: 200 ug, 1 times / day Sources: |
unhealthy, children |
Epistaxis | serious, 1 patient | 200 ug 1 times / day steady, respiratory Dose: 200 ug, 1 times / day Route: respiratory Route: steady Dose: 200 ug, 1 times / day Sources: |
unhealthy, children |
Laryngitis | serious, 1 patient | 200 ug 1 times / day steady, respiratory Dose: 200 ug, 1 times / day Route: respiratory Route: steady Dose: 200 ug, 1 times / day Sources: |
unhealthy, children |
Myringoplasty | serious, 1 patient | 200 ug 1 times / day steady, respiratory Dose: 200 ug, 1 times / day Route: respiratory Route: steady Dose: 200 ug, 1 times / day Sources: |
unhealthy, children |
Asthenia | below serious, 1 patient | 200 ug 1 times / day steady, respiratory Dose: 200 ug, 1 times / day Route: respiratory Route: steady Dose: 200 ug, 1 times / day Sources: |
unhealthy |
Chest pain | below serious, 1 patient | 200 ug 1 times / day steady, respiratory Dose: 200 ug, 1 times / day Route: respiratory Route: steady Dose: 200 ug, 1 times / day Sources: |
unhealthy |
Decreased activity | below serious, 1 patient | 200 ug 1 times / day steady, respiratory Dose: 200 ug, 1 times / day Route: respiratory Route: steady Dose: 200 ug, 1 times / day Sources: |
unhealthy |
Cough | below serious, 2 patients | 200 ug 1 times / day steady, respiratory Dose: 200 ug, 1 times / day Route: respiratory Route: steady Dose: 200 ug, 1 times / day Sources: |
unhealthy |
Overview
CYP3A4 | CYP2C9 | CYP2D6 | hERG |
---|---|---|---|
OverviewOther
Other Inhibitor | Other Substrate | Other Inducer |
---|---|---|
Drug as perpetrator
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
Page: 44.0 |
no | |||
Page: 14.0 |
no | |||
Page: 44.0 |
no | |||
Page: 14.0 |
no | |||
Page: 5.0 |
no | |||
Page: 44.0 |
no | |||
Page: 5.0 |
no | |||
Page: 44.0 |
no | |||
Page: 44.0 |
no | |||
Page: 44.0 |
no | |||
Page: 14.0 |
no | |||
Page: 44.0 |
no | |||
Page: 14, 24 |
yes [IC50 0.734 uM] | |||
Page: 14, 24 |
yes [IC50 2.4 uM] | |||
Page: 14, 24 |
yes [Inhibition 3 uM] | |||
Page: 14, 24 |
yes [Inhibition 3 uM] | |||
yes | ||||
Sources: https://pubmed.ncbi.nlm.nih.gov/22464980/ |
yes | |||
yes |
Drug as victim
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
Page: 46.0 |
inconclusive | |||
Page: 44.0 |
minor | |||
Page: 45.0 |
yes | |||
Page: 8.0 |
yes | |||
Page: 45.0 |
yes | |||
Page: 41.0 |
yes | |||
Page: 44, 101 |
yes | |||
Page: 45.0 |
yes | |||
Page: 8.0 |
yes | yes (co-administration study) Comment: ketoconazole increased ciclesonide AUC by 3.6-fold Page: 8.0 |
PubMed
Title | Date | PubMed |
---|---|---|
Formation of fatty acid conjugates of ciclesonide active metabolite in the rat lung after 4-week inhalation of ciclesonide. | 2005 |
|
[Ciclesonide in the treatment of patients with bronchial asthma]. | 2005 Dec |
|
Once-daily ciclesonide improves lung function and is well tolerated by patients with mild-to-moderate persistent asthma. | 2005 Dec |
|
Comparison of the efficacy of ciclesonide 160 microg QD and budesonide 200 microg BID in adults with persistent asthma: a phase III, randomized, double-dummy, open-label study. | 2005 Nov |
|
Gateways to clinical trials. | 2005 Oct |
|
[Ciclesonide -- a new inhaled corticosteroid]. | 2005 Oct |
|
Identification of enzymes involved in phase I metabolism of ciclesonide by human liver microsomes. | 2005 Oct-Dec |
|
Gateways to clinical trials. | 2005 Sep |
|
Ciclesonide, a novel inhaled steroid, does not affect hypothalamic-pituitary-adrenal axis function in patients with moderate-to-severe persistent asthma. | 2005 Sep |
|
Equivalent pharmacokinetics of the active metabolite of ciclesonide with and without use of the AeroChamber Plus spacer for inhalation. | 2006 |
|
Comparable efficacy of ciclesonide once daily versus fluticasone propionate twice daily in asthma. | 2006 |
|
Gateways to clinical trials. | 2006 Apr |
|
Safety, tolerability, and exposure of ciclesonide nasal spray in healthy and asymptomatic subjects with seasonal allergic rhinitis. | 2006 Apr |
|
[AIDA--results of a large post-marketing product surveillance study of maintenance asthma therapy with once-daily ciclesonide]. | 2006 Apr 6 |
|
The systemic safety of inhaled corticosteroid therapy: a focus on ciclesonide. | 2006 Aug |
|
Modulation of p-glycoprotein and breast cancer resistance protein by some prescribed corticosteroids. | 2006 Feb 15 |
|
[In persistent asthma always think of antiinflammatory agents. Inhaled corticoids as basic medication in guideline specified asthma therapy]. | 2006 Jan 19 |
|
Gateways to clinical trials. | 2006 Jan-Feb |
|
Developing the ideal inhaled corticosteroid. | 2006 Jul |
|
Gateways to clinical trials. | 2006 Jul-Aug |
|
A multinational, 12-week, randomized study comparing the efficacy and tolerability of ciclesonide and budesonide in patients with asthma. | 2006 Jun |
|
Gateways to clinical trials. | 2006 Jun |
|
Inhaled ciclesonide versus inhaled budesonide or inhaled beclomethasone or inhaled fluticasone for chronic asthma in adults: a systematic review. | 2006 Jun 5 |
|
Pharmacologic characteristics and adrenal suppression with newer inhaled corticosteroids: A comparison of ciclesonide and fluticasone propionate. | 2006 Mar |
|
Gateways to clinical trials. | 2006 Mar |
|
Once-daily ciclesonide in children: efficacy and safety in asthma. | 2006 Mar |
|
High lung deposition of 99mTc-labeled ciclesonide administered via HFA-MDI to patients with asthma. | 2006 Mar |
|
[The optimal dosing times of corticoids]. | 2006 Mar-Apr |
|
Ciclesonide reduces the need for oral steroid use in adult patients with severe, persistent asthma. | 2006 May |
|
Ciclesonide inhalation aerosol for persistent asthma. | 2006 May |
|
Effect of ciclesonide dose and duration of therapy on exercise-induced bronchoconstriction in patients with asthma. | 2006 May |
|
Anti-inflammatory effects of once daily low dose inhaled ciclesonide in mild to moderate asthmatic patients. | 2006 May |
|
In Vitro metabolism of ciclesonide in human lung and liver precision-cut tissue slices. | 2006 May |
|
Comparative efficacy of once-daily ciclesonide and budesonide in the treatment of persistent asthma. | 2006 May |
|
Inhaled corticosteroids in the treatment of respiratory allergy: safety vs. efficacy. | 2006 Nov |
|
Efficacy and safety of ciclesonide nasal spray for the treatment of seasonal allergic rhinitis. | 2006 Nov |
|
Effects of inhaled ciclesonide on circulating T-helper type 1/T-helper type 2 cells in atopic asthmatics after allergen challenge. | 2006 Nov |
|
Relevance of pharmacokinetics and pharmacodynamics of inhaled corticosteroids to asthma. | 2006 Nov |
|
Ciclesonide disposition and metabolism: pharmacokinetics, metabolism, and excretion in the mouse, rat, rabbit, and dog. | 2006 Nov-Dec |
|
Gateways to clinical trials. | 2006 Oct |
|
The newly developed inhaled corticosteroid ciclesonide for the treatment of asthma. | 2006 Oct |
|
A comparative study of inhaled ciclesonide 160 microg/day and fluticasone propionate 176 microg/day in children with asthma. | 2006 Oct |
|
Gateways to clinical trials. | 2006 Sep |
|
Effect of ciclesonide and fluticasone on exhaled nitric oxide in patients with mild allergic asthma. | 2006 Sep |
|
Two-dimensional and three-dimensional imaging show ciclesonide has high lung deposition and peripheral distribution: a nonrandomized study in healthy volunteers. | 2006 Summer |
|
Ciclesonide is more effective than budesonide in the treatment of persistent asthma. | 2007 |
|
Safety of inhaled corticosteroids: room for improvement. | 2007 |
|
The treatment of asthma in children: inhaled corticosteroids. | 2007 |
|
In vitro metabolism of ciclesonide in human nasal epithelial cells. | 2007 Jan |
|
In vitro activation of the corticosteroid ciclesonide in animal nasal mucosal homogenates. | 2007 Mar |
Patents
Sample Use Guides
Allergic rhinitis: The recommended dose of ciclesonide (in form of Omnaris Nasal Spray) is 200 ug per day administered as 2 sprays (50 mcg/spray) in each nostril once daily. Asthma: 80-320 ug twice daily.
Route of Administration:
Other
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/22246000
Ciclesonide at 10(-12)–10(-5) M significantly inhibited TNF-alpha stimulated MCP-1 production in human airway smooth muscle cells. IL1-stimulated MCP-1 release was also significantly inhibited in a concentration-dependent (10(-12)–10(-5) M) manner.
Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 18:28:48 GMT 2025
by
admin
on
Mon Mar 31 18:28:48 GMT 2025
|
Record UNII |
S59502J185
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
WHO-ATC |
R03BA08
Created by
admin on Mon Mar 31 18:28:48 GMT 2025 , Edited by admin on Mon Mar 31 18:28:48 GMT 2025
|
||
|
WHO-ATC |
R01AD13
Created by
admin on Mon Mar 31 18:28:48 GMT 2025 , Edited by admin on Mon Mar 31 18:28:48 GMT 2025
|
||
|
NCI_THESAURUS |
C521
Created by
admin on Mon Mar 31 18:28:48 GMT 2025 , Edited by admin on Mon Mar 31 18:28:48 GMT 2025
|
||
|
WHO-VATC |
QR03BA08
Created by
admin on Mon Mar 31 18:28:48 GMT 2025 , Edited by admin on Mon Mar 31 18:28:48 GMT 2025
|
||
|
WHO-VATC |
QR01AD13
Created by
admin on Mon Mar 31 18:28:48 GMT 2025 , Edited by admin on Mon Mar 31 18:28:48 GMT 2025
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
PP-61
Created by
admin on Mon Mar 31 18:28:48 GMT 2025 , Edited by admin on Mon Mar 31 18:28:48 GMT 2025
|
PRIMARY | |||
|
S59502J185
Created by
admin on Mon Mar 31 18:28:48 GMT 2025 , Edited by admin on Mon Mar 31 18:28:48 GMT 2025
|
PRIMARY | |||
|
m3536
Created by
admin on Mon Mar 31 18:28:48 GMT 2025 , Edited by admin on Mon Mar 31 18:28:48 GMT 2025
|
PRIMARY | Merck Index | ||
|
CHEMBL2040682
Created by
admin on Mon Mar 31 18:28:48 GMT 2025 , Edited by admin on Mon Mar 31 18:28:48 GMT 2025
|
PRIMARY | |||
|
633
Created by
admin on Mon Mar 31 18:28:48 GMT 2025 , Edited by admin on Mon Mar 31 18:28:48 GMT 2025
|
PRIMARY | |||
|
CICLESONIDE
Created by
admin on Mon Mar 31 18:28:48 GMT 2025 , Edited by admin on Mon Mar 31 18:28:48 GMT 2025
|
PRIMARY | |||
|
6546
Created by
admin on Mon Mar 31 18:28:48 GMT 2025 , Edited by admin on Mon Mar 31 18:28:48 GMT 2025
|
PRIMARY | |||
|
C65326
Created by
admin on Mon Mar 31 18:28:48 GMT 2025 , Edited by admin on Mon Mar 31 18:28:48 GMT 2025
|
PRIMARY | |||
|
126544-47-6
Created by
admin on Mon Mar 31 18:28:48 GMT 2025 , Edited by admin on Mon Mar 31 18:28:48 GMT 2025
|
PRIMARY | |||
|
6918155
Created by
admin on Mon Mar 31 18:28:48 GMT 2025 , Edited by admin on Mon Mar 31 18:28:48 GMT 2025
|
PRIMARY | |||
|
S59502J185
Created by
admin on Mon Mar 31 18:28:48 GMT 2025 , Edited by admin on Mon Mar 31 18:28:48 GMT 2025
|
PRIMARY | |||
|
SUB06236MIG
Created by
admin on Mon Mar 31 18:28:48 GMT 2025 , Edited by admin on Mon Mar 31 18:28:48 GMT 2025
|
PRIMARY | |||
|
C120481
Created by
admin on Mon Mar 31 18:28:48 GMT 2025 , Edited by admin on Mon Mar 31 18:28:48 GMT 2025
|
PRIMARY | |||
|
Ciclesonide
Created by
admin on Mon Mar 31 18:28:48 GMT 2025 , Edited by admin on Mon Mar 31 18:28:48 GMT 2025
|
PRIMARY | |||
|
DTXSID9046659
Created by
admin on Mon Mar 31 18:28:48 GMT 2025 , Edited by admin on Mon Mar 31 18:28:48 GMT 2025
|
PRIMARY | |||
|
100000081904
Created by
admin on Mon Mar 31 18:28:48 GMT 2025 , Edited by admin on Mon Mar 31 18:28:48 GMT 2025
|
PRIMARY | |||
|
DB01410
Created by
admin on Mon Mar 31 18:28:48 GMT 2025 , Edited by admin on Mon Mar 31 18:28:48 GMT 2025
|
PRIMARY | |||
|
141845-82-1
Created by
admin on Mon Mar 31 18:28:48 GMT 2025 , Edited by admin on Mon Mar 31 18:28:48 GMT 2025
|
ALTERNATIVE | |||
|
7469
Created by
admin on Mon Mar 31 18:28:48 GMT 2025 , Edited by admin on Mon Mar 31 18:28:48 GMT 2025
|
PRIMARY | |||
|
274964
Created by
admin on Mon Mar 31 18:28:48 GMT 2025 , Edited by admin on Mon Mar 31 18:28:48 GMT 2025
|
PRIMARY | RxNorm |
Related Record | Type | Details | ||
---|---|---|---|---|
|
TARGET -> AGONIST |
|
||
|
BINDER->LIGAND |
BINDING
|
||
|
METABOLIC ENZYME -> SUBSTRATE |
MAJOR
|
||
|
METABOLIC ENZYME -> SUBSTRATE |
MINOR
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
METABOLITE ACTIVE -> PRODRUG |
Des-ciclesonide has anti-inflammatory activity with affinity for the glucocorticoid receptor that is 120 times higher than the parent compound.
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
IMPURITY -> PARENT |
|
||
|
IMPURITY -> PARENT |
|
||
|
IMPURITY -> PARENT |
|
Name | Property Type | Amount | Referenced Substance | Defining | Parameters | References |
---|---|---|---|---|---|---|
Volume of Distribution | PHARMACOKINETIC |
|
INTRAVENOUS ADMINISTRATION |
|
||
ORAL BIOAVAILABILITY | PHARMACOKINETIC |
|
|
|||